Cardiovascular and cerebrovascular
Product introduction:

Allisartan Isoproxil Tablets

 

Indications

For the treatment of mild and moderate essential hypertension.


 

Declaration:

The detailed prescription information of this product should be subject to confirmation by the latest approved version of the State Food and Drug Administration. 

The product information on this website is not for pharmaceutical advertising, but presented as product knowledge for the reference of professionals in the pharmaceutical industry only. It MUST NOT be used for the diagnosis of diseases, and it CANNOT replace medical advice provided by doctors or other qualified medical professionals.



Product introduction:

Clopidogrel Bisulfate Tablets

 

Indications

Secondary prevention of atherosclerosis events in following patients:

Patients with Non-ST-segment elevation acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction), including patients undergoing a stent placement after percutaneous coronary intervention (PCI). Should be administered in conjunction with aspirin.

Patients with acute ST-elevation myocardial infarction. Should be administered in conjunction with aspirin during thrombolytic therapy.

Patients suffering from myocardial infarction (from a few days to less than 35 days), ischemic stroke (from 7 days to less than 6 months) or established peripheral arterial disease.



Declaration:

The detailed prescription information of this product should be subject to confirmation by the latest approved version of the State Food and Drug Administration.

The product information on this website is not for pharmaceutical advertising, but presented as product knowledge for the reference of professionals in the pharmaceutical industry only. It MUST NOT be used for the diagnosis of diseases, and it CANNOT replace medical advice provided by doctors or other qualified medical professionals.

Product introduction:

Bivalirudin for Injection

 

Indications

An anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI).

 

 

Declaration:

The detailed prescription information of this product should be subject to confirmation by the latest approved version of the State Food and Drug Administration.

The product information on this website is not for pharmaceutical advertising, but presented as product knowledge for the reference of professionals in the pharmaceutical industry only. It MUST NOT be used for the diagnosis of diseases, and it CANNOT replace medical advice provided by doctors or other qualified medical professionals.

Product introduction:

Pamidronate Disodium for Injection


Indications

For ostealgia caused by hypercalcemia associated with malignancy and osteolytic bone metastases.

 

 

Declaration:

The detailed prescription information of this product should be subject to confirmation by the latest approved version of the State Food and Drug Administration.

The product information on this website is not for pharmaceutical advertising, but presented as product knowledge for the reference of professionals in the pharmaceutical industry only. It MUST NOT be used for the diagnosis of diseases, and it CANNOT replace medical advice provided by doctors or other qualified medical professionals.

Product introduction:

Desloratadine Tablets

 

Indications

For the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis and chronic idiopathic urticaria.

 

 

Declaration:

The detailed prescription information of this product should be subject to confirmation by the latest approved version of the State Food and Drug Administration.

The product information on this website is not for pharmaceutical advertising, but presented as product knowledge for the reference of professionals in the pharmaceutical industry only. It MUST NOT be used for the diagnosis of diseases, and it CANNOT replace medical advice provided by doctors or other qualified medical professionals.


Product introduction:

Benazepril Hydrochloride Tablets

 

Indications

For each period of hypertension

For congestive heart failure

Adjuvant therapy for patients of congestive heart failure (NYHA grade Ⅱ-Ⅳ) with limited reaction to digitalis or diuretics

 

 

Declaration:

The detailed prescription information of this product should be subject to confirmation by the latest approved version of the State Food and Drug Administration.

The product information on this website is not for pharmaceutical advertising, but presented as product knowledge for the reference of professionals in the pharmaceutical industry only. It MUST NOT be used for the diagnosis of diseases, and it CANNOT replace medical advice provided by doctors or other qualified medical professionals.